Ipravent Respules 2ml contain Ipratropium bromide 500mcg, a bronchodilator used primarily in the management of chronic obstructive pulmonary disease (COPD) and asthma. Ipratropium is an anticholinergic agent that works by blocking the action of acetylcholine on muscarinic receptors in the airway smooth muscle, resulting in bronchodilation and improved airflow. These respules are intended for nebulization, allowing direct delivery of the medication to the respiratory tract, which facilitates rapid onset of action and minimizes systemic side effects. Ipravent Respules are indicated for the maintenance treatment of bronchospasm associated with COPD, including chronic bronchitis and emphysema, as well as for acute exacerbations of asthma where inhaled beta-agonists alone are insufficient. The usual dosage and frequency should be determined by a healthcare professional based on the severity of the condition and patient response. Common adverse effects may include dry mouth, cough, and headache, while serious side effects are rare but may include paradoxical bronchospasm. Caution is advised in patients with hypersensitivity to atropine derivatives. Ipravent Respules should be used under medical supervision, with adherence to prescribed dosing to ensure optimal therapeutic outcomes.